Theresa (“Tessa”) Matson aims to make addiction health services more accessible, acceptable, and equitable to patients. She recognizes that strong partnerships with health system leaders, clinical staff, and patients are necessary to identify unhealthy substance use and improve the treatment of substance use disorders — and she is enthusiastic about engaging stakeholders in the design and implementation of these efforts. She joined Kaiser Permanente Washington Health Research Institute (KPWHRI) in 2016 as a student intern and has held several roles since then, formally joining the KPWHRI faculty as a collaborative scientist in 2022. Dr. Matson is also an affiliate assistant professor in the Department of Health Systems and Population Health (HSPop) at the University of Washington.
With advanced training in quantitative and qualitative methodology, Dr. Matson is developing methods to improve the measurement of treatment for alcohol, cannabis, and other substance use disorders from administrative data such as electronic health records and insurance claims. She is interested in ways that measurement may perpetuate biases that persist in the social world or produce new paths for discrimination under the guise of objectivity. She currently collaborates on trials designed to improve the provision of care for opioid and substance use disorders in primary care and mental health settings. These trials, funded by the National Institute on Drug Abuse, include studies that promote equity in access to digital interventions for unhealthy substance use.
Dr. Matson earned her MPH in health services and her PhD in health systems and population health from the University of Washington. Her dissertation leveraged routinely collected data from Kaiser Permanente Washington to describe gaps and potential biases in diagnosis and treatment of cannabis use disorder and validated practical tools to improve cannabis use disorder recognition in primary care. The University of Washington School of Public Health awarded Dr. Matson the Gilbert S. Omenn Award for academic excellence.
Prior to becoming a collaborative scientist, Dr. Matson was a pre-doctoral fellow at VA Puget Sound, where she studied system-level, organizational-level, and patient-level determinants to receipt of evidence-based treatment for alcohol use disorder. She also worked as a research interventionist at KPWHRI, where she designed patient-centered interventions, coached patients in behavioral health change using motivational interviewing, and engaged research participants in projects to improve clinical tools and workflow through user-centered design principles.
She is a lifelong learner and aspiring adventurist with a tendency of collecting hobbies in her spare time. Currently, you’ll find her at Home Depot, checking out power tools for her latest home improvement project.
Lapham GT, Bobb JF, Luce C, Oliver MM, Hamilton LK, Hyun N, Hallgren KA, Matson TE. Prevalence of cannabis use disorder among primary care patients with varying frequency of past-year cannabis use. J Gen Intern Med. 2024 Oct 24. doi: 10.1007/s11606-024-09061-6. [Epub ahead of print]. PubMed
Steel TL, Matson TE, Hallgren KA, Oliver M, Jack HE, Berger D, Bradley KA. Incidence of hospitalizations involving alcohol withdrawal syndrome in a primary care population. JAMA Netw Open. 2024;7(10):e2438128. doi: 10.1001/jamanetworkopen.2024.38128. PubMed
Williams EC, Matson TE, Hallgren KA, Oliver M, Wang X, Bradley KA. Assessing substance use disorder symptoms with a checklist among primary care patients with opioid use disorder and/or long-term opioid treatment: An observational study. J Gen Intern Med. 2024;39(12):2169-2178. doi: 10.1007/s11606-024-08845-0. Epub 2024 Jul 1. PubMed
Matson TE, Lee AK, Oliver M, Bradley KA, Hallgren KA. Equivalence of alcohol use disorder symptom assessments completed remotely via online patient portals versus in-clinic via paper questionnaires: Psychometric evaluation. J Med Internet Res. 2024 Jul 22:26:e52101. doi: 10.2196/52101. PubMed
Hamilton LK, Bradley KA, Matson TE, Lapham GT. Discriminative validity of a substance use symptom checklist for moderate-severe DSM-5 cannabis use disorder (CUD) in primary care settings. Drug Alcohol Depend Rep. 2024 Jul 15:12:100260. doi: 10.1016/j.dadr.2024.100260. eCollection 2024 Sep. PubMed
A simple checklist developed at KPWHRI does well at measuring symptoms of substance use disorder.
Use in pregnancy and screening in primary care studied by KPWHRI’s Kiel, Matson, and Lapham.
New research examines providers’ notes to understand patients’ cannabis use and health conditions.
Healio, June 13, 2023